Groups Demand RFK Jr. ‘Immediately’ Restore CDC’s Axed Blood Division

The Crucial Role of CDC’s Division of Blood Disorders

The CDC's Division of Blood Disorders and Public Health Genomics has long been instrumental in combating blood-related diseases across the United States. Established to provide public health leadership, the division collaborates with states, healthcare providers, and patients to mitigate the impact of serious blood disorders. Its work encompasses surveillance, research, education, and program implementation aimed at improving diagnosis, treatment, and patient outcomes.

Among its many critical responsibilities, the division manages the Sickle Cell Data Collection Program, which since 2015 has gathered comprehensive data on approximately 100,000 Americans living with sickle cell disease. This program tracks trends in diagnosis, treatment accessibility, and healthcare disparities, providing essential information to policymakers and healthcare professionals.

In addition to sickle cell disease, the division oversees programs related to hemophilia, thalassemia, and blood clot awareness, ensuring that patients receive education and access to life-saving therapies. The division’s history also includes pivotal work dating back to the 1980s tainted blood crisis, where CDC investigators were first to recognize and warn about HIV transmission via blood products.

The Impact of the Division’s Abrupt Dismantlement

The recent restructuring within HHS, which placed nearly all DBDPHG staff on administrative leave, has raised alarm among health advocates and medical experts. The sudden nature of this action, with little to no communication regarding the division’s future, threatens to disrupt ongoing programs that millions rely on for their health and well-being.

ASH and nearly 100 other organizations emphasize that this decision risks increasing preventable hospitalizations and complications among individuals with chronic and acute blood disorders. Without the division’s coordinated federal response, patients could experience gaps in care, delayed diagnoses, and reduced access to critical treatments.

Moreover, the loss of the division’s research efforts could stall progress in understanding blood disorders and developing innovative therapies. The elimination of this specialized public health infrastructure contradicts the administration’s stated commitment to addressing chronic diseases and improving health outcomes for vulnerable populations.

Voices of the Medical Community and Advocacy Groups

The American Society of Hematology, a leading professional organization, has been outspoken about the consequences of the division’s dissolution. ASH President Dr. Belinda Avalos warned that eliminating the division would have “severe and irreversible consequences” for public health programs and research.

In an open letter to HHS Secretary Robert F. Kennedy Jr., ASH and 95 other organizations representing over a million Americans with blood disorders urged the immediate reinstatement of the division. Their collective message stresses that the division’s work is indispensable for reducing health disparities and improving clinical outcomes.

These groups also highlighted the division’s role in patient and physician education, which raises awareness about conditions like blood clots and thalassemia. They argue that dismantling this division undermines decades of progress and endangers the lives of thousands who depend on its programs.

Historical Significance: Lessons from the 1980s Tainted Blood Crisis

The Division of Blood Disorders traces its roots to the public health response following the 1980s tainted blood crisis. During this period, an estimated 90% of the U.S. hemophilia population contracted HIV or hepatitis C through contaminated plasma-derived clotting factor products.

CDC investigators played a critical role in identifying and warning about the transmissibility of HIV via blood products, which led to improved blood safety regulations and screening protocols. This historical success underscores the division’s vital role in protecting public health through vigilant surveillance and rapid response.

The dismantling of the division raises concerns that the U.S. could lose a crucial safeguard against emerging threats related to blood safety. Experts worry that without this specialized unit, the country may be less prepared to detect or respond to future bloodborne pathogen risks.

Potential Consequences for Patients with Blood Disorders

Blood disorders such as hemophilia, sickle cell disease, and thalassemia require ongoing surveillance, specialized care, and public health intervention to manage effectively. The division’s programs have been essential in coordinating these efforts nationwide, ensuring patients receive timely and appropriate care.

Without the division’s infrastructure, patients face increased risks of preventable complications and hospitalizations. For example, the Sickle Cell Data Collection Program has helped identify gaps in care and improve access to treatments that reduce painful crises and organ damage.

The loss of federal coordination could exacerbate existing health disparities, particularly affecting minority populations disproportionately impacted by these disorders. Advocacy groups warn that dismantling the division endangers the progress made in reducing morbidity and mortality among these vulnerable groups.

Calls for Immediate Action and Restoration

In response to the dismantling, a coalition of nearly 100 national and state organizations has formally demanded the immediate restoration of the Division of Blood Disorders and Public Health Genomics. Their letter to Secretary RFK Jr. highlights the urgent need to reinstate the division to prevent a public health crisis.

These groups emphasize that the division’s work aligns closely with the administration’s broader goals of addressing chronic disease and improving health equity. Reinstating the division would demonstrate a commitment to the millions living with blood disorders who rely on its programs.

Furthermore, ASH intends to share this letter with key members of Congress to garner legislative support for restoring funding and resources. The coalition’s unified stance reflects the critical importance of preserving specialized federal public health programs dedicated to blood disorders.

Broader Implications for Public Health Infrastructure

The dismantling of the DBDPHG raises broader concerns about the stability and prioritization of specialized public health divisions within the CDC and HHS. Experts warn that such abrupt restructuring without clear communication undermines public trust and disrupts essential health services.

Blood disorders represent just one area where federal coordination is vital; similar divisions address other chronic diseases and health threats. The removal of targeted programs risks fragmenting care and weakening the nation’s ability to respond effectively to complex health challenges.

This situation highlights the need for transparent decision-making and stakeholder engagement when restructuring public health agencies. Maintaining robust infrastructure and specialized expertise is critical to safeguarding population health and advancing medical research.

Conclusion

The abrupt dismantling of the CDC’s Division of Blood Disorders and Public Health Genomics represents a significant setback in the nation’s efforts to manage chronic and acute blood disorders. The division’s critical programs have long provided indispensable surveillance, education, and research that protect millions of Americans. The unified demand from ASH and nearly 100 other organizations for immediate restoration underlines the dire consequences of this decision. Moving forward, it is imperative for HHS leadership, including Secretary Robert F. Kennedy Jr., to prioritize the reinstatement of this division to safeguard public health, advance research, and ensure equitable care for vulnerable populations. Maintaining strong, specialized federal public health programs remains essential to addressing complex health challenges and improving outcomes for all Americans.